IL15 and neoplasm: Similarly, 50% (4/8) of the treated SK-BR-3 HTM had no, or only a very low level of tumor burden left in the peritoneum upon IL-15/trastuzumab treatment (Figure 2F), whereas trastuzumab therapy alone was not sufficient to reduce the amount of tumor cells in any of the treated mice.